Mirati's SAPPHIRE trial in NSCLC terminated, results posted on ClinicalTrials.gov
The sitravatinib-nivolumab combination missed its goal against docetaxel, with overall survival data posted for the terminated phase 3 study.
ClinicalTrials.gov
Latest
23 stories
Yesterday
BMS registers Phase 1 CAR T cell trial in kidney cancer; adds mavacamten real-world study
Tuesday, September 29
Altimmune names Richard Menziuso as principal accounting officer
The appointment, effective September 29, 2026, keeps Gregory Weaver as chief financial officer.
SEC filing
Friday, September 25
BMS trials update: CheckMate-67T posts results; two studies added for irAE care and lung screening
Thursday, September 17
Faeth Therapeutics expands board, adds co-founder Karen Vousden
The cancer biologist and Faeth co-founder joins as a sixth director, seated on the Compensation Committee, per a September 17 8-K.
SEC filing
Friday, September 11
Incyte posts terminated Phase 1 KRASG12C combo results; registers new INCB161734 mass balance study
Wednesday, September 2
BMS logs three FDA label approvals and posts results for melanoma combo trial
Thursday, August 27
BMS registers new deucravacitinib continuation study; prior week's trial results still stand
Friday, August 21
BMS registers Phase 2 depression trial for BMS-986511; adds Alzheimer's PK study for BMS-986446
Thursday, August 13
FDA approves Bristol Myers Squibb's Zenbexus, a new molecular entity
The agency granted priority review approval to iberdomide hydrochloride capsules for oral use, with an approval letter dated August 17, 2026.
Drugs@FDA
Atrium Therapeutics clears IND for ATR 1072, activates first Corventis sites for PRKAG2 syndrome
The company also banked a second $15 million Bristol Myers Squibb milestone and reported cash runway into mid-2028.
SEC filing
BMS posts JAKARTA Phase 3 results, updates Opdivo label, registers golcadomide renal study
Zenas BioPharma reports Q2 2026 results, obexelimab BLA now accepted by FDA
FDA accepted the IgG4-RD application with a target decision date in May 2027, while the company posted a wider quarterly net loss and $673.9 million in cash.
SEC filing
Calidi gets FDA pre-IND feedback on CLD-401, still targets Q1 2027 first dose
The company said the FDA agreed with its development strategy for the RedTail program's lead candidate, keeping the first-in-human study on track for early 2027.
SEC filing
Friday, August 7
Bristol-Myers Squibb registers observational study of first-line Reblozyl in lower-risk MDS
Thursday, August 6
Prothena reports Q2 2026 results, updates year-end cash guidance to $259 million
Roche published Phase 2b PADOVA data on prasinezumab in The Lancet while Prothena trimmed its 2026 cash forecast after share buybacks.
SEC filing
Wednesday, August 5
Arcus Biosciences advances casdatifan combinations, reports $775M cash at midyear 2026
Arcus added three new clinical collaborations for its HIF-2α inhibitor casdatifan and said cash runway extends to at least the second half of 2028.
SEC filing
Schrodinger launches Bunsen AI co-scientist, raises 2026 drug discovery revenue outlook
The company reported second-quarter ACV growth of 27% and lifted its full-year drug discovery revenue guidance after an Ajax Therapeutics milestone payment.
SEC filing
Tuesday, August 4
BioNTech names Guido Oelkers CEO, trims 2026 revenue guidance in Q2 update
The company reported a wider net loss and cut its full-year revenue outlook to €1.6–1.9 billion while confirming Oelkers will succeed Ugur Sahin by February 2027.
SEC filing (2)
Thursday, July 30
Results post for old USC gastric cancer trial; Bristol Myers Squibb opens new Zeposia PML study
Bristol Myers Squibb raises 2026 guidance, cites pipeline progress across four programs
The company raised full-year revenue and EPS guidance and disclosed new regulatory and trial milestones for Reblozyl, mezigdomide, Camzyos and iza-bren.
SEC filing